SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing increased selling pressure following the emergence and subsequent denial of acquisition rumors involving Lionsgate Studios, fueling community frustration over management's deal-making strategies. Investors are actively debating whether to capitalize on the recent price dip or scale out of positions, while many call for more aggressive execution of share buybacks to stabilize the stock.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc is trending as investors closely watch the upcoming AR spectacles unveiling, which is driving significant debate regarding the company's hardware strategy and potential for mass market adoption. Community members are actively split between those betting on the long-term value of the companys extensive patent portfolio and patent-heavy AR ecosystem, and those expressing skepticism over the product's premium price point and the leadership's ability to drive profitability.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor the company's aggressive legal move to reclaim commercial rights from Nippon Shinyaku, coupled with the strategic appointment of a veteran commercial officer ahead of the crucial FDA decision for deramiocel. The community is heavily focused on the potential for Capricor to launch the product independently, interpreting these developments as a major de-risking event that could unlock significant upside.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors digest news of a potential shift in corporate leadership and anticipation surrounding a binding tenant announcement. Community sentiment remains split between excitement over high-beta exposure to AI energy infrastructure and intense skepticism fueled by boardroom drama and past execution delays.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure shares are rallying following a leadership change at the FDA's gene therapy division, which investors believe will lead to more flexible regulatory reviews for its AMT-130 Huntington's disease treatment. The community is actively discussing the stock's potential for a significant turnaround, with many citing analyst upgrades and renewed optimism for accelerated approval pathways.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as investors debate the impact of executive stock sales and sector-wide rotations against strong quarterly performance and enterprise growth. The community remains polarized, with some focusing on potential short-squeeze opportunities and bullish AI integration potential, while others express frustration over downward price pressure and institutional selling.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as the community remains divided over a recent production order announcement that notably omitted specific financial details. While some investors view the news as a critical validation of Aehr's wafer-level burn-in technology for the expanding silicon photonics and AI data center sectors, others remain skeptical, pointing to the lack of transparent order values and high valuation multiples relative to current revenue.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is currently attracting significant community attention as investors await clarity on the AXPAXLI NDA submission timeline following recent trial data. The stock is experiencing heightened volatility and intense debate, with many participants focused on the high institutional ownership and conflicting sentiment regarding the strength of its clinical results compared to existing standards of care.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending as investors debate the impact of new defense contracts and swarm technology milestones against the backdrop of significant short interest and concerns regarding potential share dilution. The community remains sharply divided between retail traders betting on a short squeeze and long-term supporters focused on the company's strategic transition into a vertically integrated defense manufacturer.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as traders closely monitor developments regarding potential acquisition interest, with the company currently positioned as a key topic in media sector M&A conversations. Community discussion is focused on analyzing the feasibility of rumored takeover interest while evaluating the stock's recent price volatility and the impact of the streaming landscape on its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ARBK let’s say for instance that Argo goes bankrupt and another company buys them out, would we as shareholders lose all our money as the shares would ‘disappear’ or would the shares we had go into the new company that bought us out? 
How does it work?

StockTwits for iOS

Argo Blockchain Plc

 let’s say for instance that Argo goes bankrupt and another company buys them out, would we as shareholders lose all our money as the shares would ‘disappear’ or would the shares we had go into the new company that bought us out? 
How does it work?

Sami

@Samispeed The new company would agree to buy the company for a set price. Let&#39;s say they buy the company for $200M, just for round numbers. That would be a price of $4.19 per share based on the current total outstanding shares. Essentially, your shares would be bought from you at that price and you would receive cash ($4.19 for every share you own). Sometimes the deals are structured based on the share price directly, meaning the new company would just agree to buy the company for a flat $2 per share. It&#39;s essentially the same thing, but $2 would only be a $103M valuation (which is where it&#39;s at right now).

StockTwits Web

 The new company would agree to buy the company for a set price. Let's say they buy the company for $200M, just for round numbers. That would be a price of $4.19 per share based on the current total outstanding shares. Essentially, your shares would be bought from you at that price and you would receive cash ($4.19 for every share you own). Sometimes the deals are structured based on the share price directly, meaning the new company would just agree to buy the company for a flat $2 per share. It's essentially the same thing, but $2 would only be a $103M valuation (which is where it's at right now).

Matthew Avery

@Apocalypse_Meow @Samispeed you&#39;re forgetting the bankrupt part, if it was bankrupt it would be nowehere near the price it is now, cos its gone bankrupt...., bondholders have more rights than shareholders, trust me if this goes bankrupt you end up with little or zero as a shareholder.

 you're forgetting the bankrupt part, if it was bankrupt it would be nowehere near the price it is now, cos its gone bankrupt...., bondholders have more rights than shareholders, trust me if this goes bankrupt you end up with little or zero as a shareholder.